Telehealth M&A Multiples Hit 2–3x Revenue as Behavioral Health Consolidates

M&A Valuations Reset Enterprise Telehealth Pricing Expectations

Telehealth M&A activity re-accelerated in 2024 and into early 2025 after a two-year trough, establishing new valuation benchmarks that directly affect enterprise buyer negotiations and vendor risk assessments. Recent transactions show strategic buyers paying 2–3x revenue for scaled behavioral health and diagnostics platforms — a concrete data point for procurement teams evaluating vendor stability and pricing.

Teladoc acquired UpLift, a behavioral health platform, on April 30, 2025 for $30 million plus up to $15 million earnout on approximately $15 million in 2024 revenue. That implies roughly 2.0x EV/revenue, or 3.0x including the earnout. Two months earlier, Teladoc announced the acquisition of Catapult Health, a virtual preventive care and at-home diagnostics provider, for $65 million plus up to $5 million earnout on about $30 million trailing twelve-month revenue — approximately 2.17x EV/revenue.

These multiples give CIOs and CFOs a sanity check on vendor valuations. A telepsychiatry or diagnostics platform claiming hypergrowth but seeking prices that imply 5–7x revenue multiples is either overvalued or faces serious retention or margin issues. Conversely, vendors trading below 2x revenue with shrinking top lines become higher continuity risks.

Strategic Buyers Want Distribution, Not Visit Volume

The pattern in recent telehealth M&A is clear: acquirers are buying capabilities and covered-lives distribution rather than pure visit volume. Teladoc's two acquisitions add behavioral health depth and at-home diagnostics to its integrated platform, not standalone telehealth video functionality.

For enterprise buyers evaluating dedicated telepsychiatry vendors — InSight, Regroup, Aligned Telehealth — this shift matters. Those vendors must now compete against integrated platforms that bundle behavioral health into broader virtual-care contracts. The value proposition of a best-of-breed telepsychiatry point solution weakens if it cannot demonstrate superior network adequacy, faster clinician onboarding, or materially better outcomes than what a health system or payer can get from Teladoc or a similar integrated platform.

Renewal conversations should explicitly probe whether vendors are potential acquisition targets, by whom, and how they will maintain network adequacy, licensure footprint, and clinician onboarding standards post-M&A. The M&A data confirms these are the operational capabilities buyers and acquirers care about, not feature lists.

Market Projections Support Multi-Year Budget Lines

The global telehealth market is projected to reach $36.5 billion by 2032, growing at a 17.3% compound annual growth rate from 2022. In the US specifically, the telehealth market will reach approximately $36.1 billion in 2026, with 15,500-plus active businesses. Industry forecasts estimate 25–30% of all US medical visits will be virtual by year-end 2026.

These projections underpin multi-year telehealth line items in capital and operating budgets. CFOs are less likely to treat telehealth platforms as temporary pilots or discretionary spend. The 17.3% global CAGR and 25–30% virtual visit penetration justify durable investment.

The flip side: a crowded vendor landscape with 15,500-plus US telehealth businesses means commodity video-visit vendors are easily replaceable. Platforms differentiate via EHR integration depth, diagnostics-at-home capabilities, pharmacy enablement, specialty clinical depth, and data and analytics that feed into population health and risk stratification workflows.

RFP Criteria Tighten as Market Matures

With a mature and crowded market, procurement teams are tightening RFP criteria. Buyers now demand Business Associate Agreements, HIPAA and SOC 2 documentation, and proof of healthcare-specific security controls up front, not during contract negotiation. Documented EHR integrations with Epic, Oracle Health, and athenahealth are table stakes for shortlisting.

Vendor consolidation risk is real. High vendor count plus ongoing M&A means procurement should favor vendors with either strong covered-lives distribution through payers and employers or embedded health-system relationships. Change-of-control clauses and data-export guarantees belong in every telehealth platform contract to mitigate acquisition risk.

The M&A report recommends that in the next 6–18 months, health systems and payers add in-network behavioral health and diagnostics-at-home capabilities, either via acquisition or deep partnerships, to reduce structural risk and improve unit economics. That directly informs whether to buy from a single integrated platform versus assembling a best-of-breed stack.

What to Watch

Monitor whether your current telepsychiatry or diagnostics vendor is fundraising or fielding acquisition interest. Vendors valued below 2x revenue with flat or declining revenue are higher continuity risks. If your organization is planning RFPs in the next six months, use the 2–3x revenue benchmark to assess vendor pricing and financial health. For health systems and payers, the market data supports a strategic decision: build or buy integrated behavioral health and diagnostics capabilities now, before unit economics and competitive dynamics force a reactive move.